nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—UGT2B7—urinary bladder cancer	0.417	1	CbGaD
Ezetimibe—ABCC3—Fluorouracil—urinary bladder cancer	0.0349	0.0915	CbGbCtD
Ezetimibe—UGT2B7—Epirubicin—urinary bladder cancer	0.0323	0.0847	CbGbCtD
Ezetimibe—ABCC3—Cisplatin—urinary bladder cancer	0.0296	0.0777	CbGbCtD
Ezetimibe—ABCC3—Etoposide—urinary bladder cancer	0.0291	0.0764	CbGbCtD
Ezetimibe—UGT1A1—Etoposide—urinary bladder cancer	0.0218	0.0571	CbGbCtD
Ezetimibe—ABCB1—Mitomycin—urinary bladder cancer	0.021	0.0551	CbGbCtD
Ezetimibe—ABCC3—Doxorubicin—urinary bladder cancer	0.0199	0.0521	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—urinary bladder cancer	0.0192	0.0505	CbGbCtD
Ezetimibe—ABCC2—Carboplatin—urinary bladder cancer	0.0158	0.0413	CbGbCtD
Ezetimibe—ABCG2—Fluorouracil—urinary bladder cancer	0.0143	0.0376	CbGbCtD
Ezetimibe—ABCG2—Carboplatin—urinary bladder cancer	0.0143	0.0374	CbGbCtD
Ezetimibe—ABCC2—Cisplatin—urinary bladder cancer	0.0135	0.0353	CbGbCtD
Ezetimibe—ABCC2—Etoposide—urinary bladder cancer	0.0132	0.0347	CbGbCtD
Ezetimibe—ABCG2—Cisplatin—urinary bladder cancer	0.0122	0.0319	CbGbCtD
Ezetimibe—ABCG2—Etoposide—urinary bladder cancer	0.012	0.0314	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—urinary bladder cancer	0.00995	0.0261	CbGbCtD
Ezetimibe—CYP3A4—Thiotepa—urinary bladder cancer	0.00954	0.025	CbGbCtD
Ezetimibe—ABCC2—Doxorubicin—urinary bladder cancer	0.00903	0.0237	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—urinary bladder cancer	0.00875	0.0229	CbGbCtD
Ezetimibe—ABCG2—Doxorubicin—urinary bladder cancer	0.00816	0.0214	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—urinary bladder cancer	0.00791	0.0207	CbGbCtD
Ezetimibe—ABCB1—Gemcitabine—urinary bladder cancer	0.00604	0.0159	CbGbCtD
Ezetimibe—ABCG8—prostate gland—urinary bladder cancer	0.00518	0.107	CbGeAlD
Ezetimibe—ABCB1—Cisplatin—urinary bladder cancer	0.00439	0.0115	CbGbCtD
Ezetimibe—ABCB1—Etoposide—urinary bladder cancer	0.00431	0.0113	CbGbCtD
Ezetimibe—UGT1A1—urine—urinary bladder cancer	0.00315	0.0651	CbGeAlD
Ezetimibe—ABCB1—Doxorubicin—urinary bladder cancer	0.00294	0.00772	CbGbCtD
Ezetimibe—ABCB1—Methotrexate—urinary bladder cancer	0.00285	0.00748	CbGbCtD
Ezetimibe—CYP3A4—Etoposide—urinary bladder cancer	0.00259	0.00678	CbGbCtD
Ezetimibe—UGT2B15—prostate gland—urinary bladder cancer	0.00217	0.045	CbGeAlD
Ezetimibe—SOAT1—prostate gland—urinary bladder cancer	0.00187	0.0387	CbGeAlD
Ezetimibe—ANPEP—prostate gland—urinary bladder cancer	0.00179	0.037	CbGeAlD
Ezetimibe—CYP3A4—Doxorubicin—urinary bladder cancer	0.00176	0.00462	CbGbCtD
Ezetimibe—SOAT1—seminal vesicle—urinary bladder cancer	0.00158	0.0327	CbGeAlD
Ezetimibe—ANPEP—seminal vesicle—urinary bladder cancer	0.00151	0.0313	CbGeAlD
Ezetimibe—UGT2B15—urethra—urinary bladder cancer	0.00146	0.0301	CbGeAlD
Ezetimibe—UGT2B7—prostate gland—urinary bladder cancer	0.00133	0.0275	CbGeAlD
Ezetimibe—SOAT1—smooth muscle tissue—urinary bladder cancer	0.00132	0.0274	CbGeAlD
Ezetimibe—ANPEP—epithelium—urinary bladder cancer	0.00131	0.0272	CbGeAlD
Ezetimibe—SOAT1—renal system—urinary bladder cancer	0.00127	0.0264	CbGeAlD
Ezetimibe—ANPEP—smooth muscle tissue—urinary bladder cancer	0.00127	0.0262	CbGeAlD
Ezetimibe—SOAT1—urethra—urinary bladder cancer	0.00125	0.0259	CbGeAlD
Ezetimibe—ANPEP—renal system—urinary bladder cancer	0.00122	0.0252	CbGeAlD
Ezetimibe—ANPEP—urethra—urinary bladder cancer	0.0012	0.0248	CbGeAlD
Ezetimibe—UGT2B15—female reproductive system—urinary bladder cancer	0.00119	0.0245	CbGeAlD
Ezetimibe—UGT1A1—prostate gland—urinary bladder cancer	0.00113	0.0234	CbGeAlD
Ezetimibe—SOAT1—female reproductive system—urinary bladder cancer	0.00102	0.0211	CbGeAlD
Ezetimibe—CYP3A4—urine—urinary bladder cancer	0.00101	0.0209	CbGeAlD
Ezetimibe—ANPEP—female reproductive system—urinary bladder cancer	0.000976	0.0202	CbGeAlD
Ezetimibe—SOAT1—vagina—urinary bladder cancer	0.000923	0.0191	CbGeAlD
Ezetimibe—UGT2B7—renal system—urinary bladder cancer	0.000905	0.0187	CbGeAlD
Ezetimibe—ABCC3—prostate gland—urinary bladder cancer	0.000892	0.0184	CbGeAlD
Ezetimibe—ANPEP—vagina—urinary bladder cancer	0.000883	0.0183	CbGeAlD
Ezetimibe—UGT1A1—renal system—urinary bladder cancer	0.00077	0.0159	CbGeAlD
Ezetimibe—UGT2B7—female reproductive system—urinary bladder cancer	0.000725	0.015	CbGeAlD
Ezetimibe—ABCC2—prostate gland—urinary bladder cancer	0.000712	0.0147	CbGeAlD
Ezetimibe—SLCO1B1—renal system—urinary bladder cancer	0.00064	0.0132	CbGeAlD
Ezetimibe—ABCC3—renal system—urinary bladder cancer	0.000608	0.0126	CbGeAlD
Ezetimibe—SOAT1—lymph node—urinary bladder cancer	0.000597	0.0124	CbGeAlD
Ezetimibe—ANPEP—lymph node—urinary bladder cancer	0.000571	0.0118	CbGeAlD
Ezetimibe—ABCG2—prostate gland—urinary bladder cancer	0.00052	0.0107	CbGeAlD
Ezetimibe—SLCO1B1—female reproductive system—urinary bladder cancer	0.000513	0.0106	CbGeAlD
Ezetimibe—ABCC3—female reproductive system—urinary bladder cancer	0.000487	0.0101	CbGeAlD
Ezetimibe—ABCC2—renal system—urinary bladder cancer	0.000486	0.01	CbGeAlD
Ezetimibe—ABCG2—seminal vesicle—urinary bladder cancer	0.000439	0.00909	CbGeAlD
Ezetimibe—ABCC2—female reproductive system—urinary bladder cancer	0.000389	0.00804	CbGeAlD
Ezetimibe—ABCG2—urethra—urinary bladder cancer	0.000348	0.00719	CbGeAlD
Ezetimibe—ABCC3—lymph node—urinary bladder cancer	0.000285	0.00589	CbGeAlD
Ezetimibe—ABCG2—vagina—urinary bladder cancer	0.000256	0.00531	CbGeAlD
Ezetimibe—ABCB1—prostate gland—urinary bladder cancer	0.000256	0.0053	CbGeAlD
Ezetimibe—CYP3A4—renal system—urinary bladder cancer	0.000247	0.0051	CbGeAlD
Ezetimibe—ABCC2—lymph node—urinary bladder cancer	0.000227	0.00471	CbGeAlD
Ezetimibe—ABCB1—seminal vesicle—urinary bladder cancer	0.000217	0.00448	CbGeAlD
Ezetimibe—CYP3A4—female reproductive system—urinary bladder cancer	0.000198	0.00409	CbGeAlD
Ezetimibe—ABCB1—epithelium—urinary bladder cancer	0.000188	0.00389	CbGeAlD
Ezetimibe—ABCB1—renal system—urinary bladder cancer	0.000175	0.00361	CbGeAlD
Ezetimibe—ABCB1—urethra—urinary bladder cancer	0.000172	0.00355	CbGeAlD
Ezetimibe—ABCG2—lymph node—urinary bladder cancer	0.000166	0.00343	CbGeAlD
Ezetimibe—ABCB1—female reproductive system—urinary bladder cancer	0.00014	0.00289	CbGeAlD
Ezetimibe—ABCB1—vagina—urinary bladder cancer	0.000126	0.00262	CbGeAlD
Ezetimibe—Infestation—Methotrexate—urinary bladder cancer	9.28e-05	0.00125	CcSEcCtD
Ezetimibe—Gastritis—Doxorubicin—urinary bladder cancer	9.22e-05	0.00124	CcSEcCtD
Ezetimibe—Pain—Cisplatin—urinary bladder cancer	9.22e-05	0.00124	CcSEcCtD
Ezetimibe—Muscular weakness—Doxorubicin—urinary bladder cancer	9.19e-05	0.00124	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	9.19e-05	0.00124	CcSEcCtD
Ezetimibe—Body temperature increased—Gemcitabine—urinary bladder cancer	9.14e-05	0.00123	CcSEcCtD
Ezetimibe—Dizziness—Thiotepa—urinary bladder cancer	9.09e-05	0.00123	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	9.05e-05	0.00122	CcSEcCtD
Ezetimibe—Urticaria—Fluorouracil—urinary bladder cancer	9.03e-05	0.00122	CcSEcCtD
Ezetimibe—Influenza—Doxorubicin—urinary bladder cancer	9.01e-05	0.00121	CcSEcCtD
Ezetimibe—Body temperature increased—Fluorouracil—urinary bladder cancer	8.99e-05	0.00121	CcSEcCtD
Ezetimibe—Eosinophilia—Doxorubicin—urinary bladder cancer	8.92e-05	0.0012	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Epirubicin—urinary bladder cancer	8.89e-05	0.0012	CcSEcCtD
Ezetimibe—Feeling abnormal—Cisplatin—urinary bladder cancer	8.88e-05	0.0012	CcSEcCtD
Ezetimibe—Paraesthesia—Etoposide—urinary bladder cancer	8.87e-05	0.0012	CcSEcCtD
Ezetimibe—Pancreatitis—Doxorubicin—urinary bladder cancer	8.83e-05	0.00119	CcSEcCtD
Ezetimibe—Dyspnoea—Etoposide—urinary bladder cancer	8.81e-05	0.00119	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Methotrexate—urinary bladder cancer	8.77e-05	0.00118	CcSEcCtD
Ezetimibe—Vomiting—Thiotepa—urinary bladder cancer	8.74e-05	0.00118	CcSEcCtD
Ezetimibe—Infestation NOS—Epirubicin—urinary bladder cancer	8.68e-05	0.00117	CcSEcCtD
Ezetimibe—Infestation—Epirubicin—urinary bladder cancer	8.68e-05	0.00117	CcSEcCtD
Ezetimibe—Rash—Thiotepa—urinary bladder cancer	8.67e-05	0.00117	CcSEcCtD
Ezetimibe—Dermatitis—Thiotepa—urinary bladder cancer	8.66e-05	0.00117	CcSEcCtD
Ezetimibe—Headache—Thiotepa—urinary bladder cancer	8.61e-05	0.00116	CcSEcCtD
Ezetimibe—Decreased appetite—Etoposide—urinary bladder cancer	8.59e-05	0.00116	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Etoposide—urinary bladder cancer	8.53e-05	0.00115	CcSEcCtD
Ezetimibe—Body temperature increased—Cisplatin—urinary bladder cancer	8.52e-05	0.00115	CcSEcCtD
Ezetimibe—Fatigue—Etoposide—urinary bladder cancer	8.51e-05	0.00115	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Epirubicin—urinary bladder cancer	8.51e-05	0.00115	CcSEcCtD
Ezetimibe—Jaundice—Epirubicin—urinary bladder cancer	8.46e-05	0.00114	CcSEcCtD
Ezetimibe—Pain—Etoposide—urinary bladder cancer	8.45e-05	0.00114	CcSEcCtD
Ezetimibe—Constipation—Etoposide—urinary bladder cancer	8.45e-05	0.00114	CcSEcCtD
Ezetimibe—Hypersensitivity—Fluorouracil—urinary bladder cancer	8.38e-05	0.00113	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	8.37e-05	0.00113	CcSEcCtD
Ezetimibe—Hepatitis—Methotrexate—urinary bladder cancer	8.33e-05	0.00112	CcSEcCtD
Ezetimibe—Asthenia—Gemcitabine—urinary bladder cancer	8.3e-05	0.00112	CcSEcCtD
Ezetimibe—Pharyngitis—Methotrexate—urinary bladder cancer	8.26e-05	0.00111	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	8.22e-05	0.00111	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Epirubicin—urinary bladder cancer	8.21e-05	0.00111	CcSEcCtD
Ezetimibe—Pruritus—Gemcitabine—urinary bladder cancer	8.18e-05	0.0011	CcSEcCtD
Ezetimibe—ABCB1—lymph node—urinary bladder cancer	8.18e-05	0.00169	CbGeAlD
Ezetimibe—Nausea—Thiotepa—urinary bladder cancer	8.17e-05	0.0011	CcSEcCtD
Ezetimibe—Sinusitis—Epirubicin—urinary bladder cancer	8.14e-05	0.0011	CcSEcCtD
Ezetimibe—Feeling abnormal—Etoposide—urinary bladder cancer	8.14e-05	0.0011	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Etoposide—urinary bladder cancer	8.08e-05	0.00109	CcSEcCtD
Ezetimibe—Pruritus—Fluorouracil—urinary bladder cancer	8.05e-05	0.00108	CcSEcCtD
Ezetimibe—Infestation NOS—Doxorubicin—urinary bladder cancer	8.03e-05	0.00108	CcSEcCtD
Ezetimibe—Infestation—Doxorubicin—urinary bladder cancer	8.03e-05	0.00108	CcSEcCtD
Ezetimibe—Hypersensitivity—Cisplatin—urinary bladder cancer	7.94e-05	0.00107	CcSEcCtD
Ezetimibe—Diarrhoea—Gemcitabine—urinary bladder cancer	7.91e-05	0.00107	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—urinary bladder cancer	7.87e-05	0.00106	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	7.87e-05	0.00106	CcSEcCtD
Ezetimibe—Urticaria—Etoposide—urinary bladder cancer	7.85e-05	0.00106	CcSEcCtD
Ezetimibe—Jaundice—Doxorubicin—urinary bladder cancer	7.83e-05	0.00106	CcSEcCtD
Ezetimibe—Body temperature increased—Etoposide—urinary bladder cancer	7.81e-05	0.00105	CcSEcCtD
Ezetimibe—Abdominal pain—Etoposide—urinary bladder cancer	7.81e-05	0.00105	CcSEcCtD
Ezetimibe—Hepatitis—Epirubicin—urinary bladder cancer	7.79e-05	0.00105	CcSEcCtD
Ezetimibe—Diarrhoea—Fluorouracil—urinary bladder cancer	7.78e-05	0.00105	CcSEcCtD
Ezetimibe—Asthenia—Cisplatin—urinary bladder cancer	7.73e-05	0.00104	CcSEcCtD
Ezetimibe—Pharyngitis—Epirubicin—urinary bladder cancer	7.73e-05	0.00104	CcSEcCtD
Ezetimibe—Oedema peripheral—Epirubicin—urinary bladder cancer	7.68e-05	0.00103	CcSEcCtD
Ezetimibe—Connective tissue disorder—Epirubicin—urinary bladder cancer	7.66e-05	0.00103	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	7.6e-05	0.00102	CcSEcCtD
Ezetimibe—Angiopathy—Methotrexate—urinary bladder cancer	7.55e-05	0.00102	CcSEcCtD
Ezetimibe—Sinusitis—Doxorubicin—urinary bladder cancer	7.54e-05	0.00102	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—urinary bladder cancer	7.52e-05	0.00101	CcSEcCtD
Ezetimibe—Dizziness—Fluorouracil—urinary bladder cancer	7.52e-05	0.00101	CcSEcCtD
Ezetimibe—Mediastinal disorder—Methotrexate—urinary bladder cancer	7.5e-05	0.00101	CcSEcCtD
Ezetimibe—Diarrhoea—Cisplatin—urinary bladder cancer	7.38e-05	0.000994	CcSEcCtD
Ezetimibe—Erythema multiforme—Epirubicin—urinary bladder cancer	7.37e-05	0.000993	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—urinary bladder cancer	7.36e-05	0.000992	CcSEcCtD
Ezetimibe—Vomiting—Gemcitabine—urinary bladder cancer	7.35e-05	0.000991	CcSEcCtD
Ezetimibe—Mental disorder—Methotrexate—urinary bladder cancer	7.3e-05	0.000984	CcSEcCtD
Ezetimibe—Rash—Gemcitabine—urinary bladder cancer	7.29e-05	0.000983	CcSEcCtD
Ezetimibe—Dermatitis—Gemcitabine—urinary bladder cancer	7.29e-05	0.000982	CcSEcCtD
Ezetimibe—Hypersensitivity—Etoposide—urinary bladder cancer	7.28e-05	0.000981	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—urinary bladder cancer	7.25e-05	0.000977	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—urinary bladder cancer	7.25e-05	0.000977	CcSEcCtD
Ezetimibe—Headache—Gemcitabine—urinary bladder cancer	7.25e-05	0.000977	CcSEcCtD
Ezetimibe—Flushing—Epirubicin—urinary bladder cancer	7.23e-05	0.000975	CcSEcCtD
Ezetimibe—Vomiting—Fluorouracil—urinary bladder cancer	7.23e-05	0.000975	CcSEcCtD
Ezetimibe—Hepatitis—Doxorubicin—urinary bladder cancer	7.21e-05	0.000972	CcSEcCtD
Ezetimibe—Rash—Fluorouracil—urinary bladder cancer	7.17e-05	0.000967	CcSEcCtD
Ezetimibe—Dermatitis—Fluorouracil—urinary bladder cancer	7.16e-05	0.000966	CcSEcCtD
Ezetimibe—Pharyngitis—Doxorubicin—urinary bladder cancer	7.16e-05	0.000965	CcSEcCtD
Ezetimibe—Headache—Fluorouracil—urinary bladder cancer	7.12e-05	0.00096	CcSEcCtD
Ezetimibe—Oedema peripheral—Doxorubicin—urinary bladder cancer	7.1e-05	0.000958	CcSEcCtD
Ezetimibe—Asthenia—Etoposide—urinary bladder cancer	7.09e-05	0.000955	CcSEcCtD
Ezetimibe—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.09e-05	0.000955	CcSEcCtD
Ezetimibe—Angiopathy—Epirubicin—urinary bladder cancer	7.07e-05	0.000953	CcSEcCtD
Ezetimibe—Immune system disorder—Epirubicin—urinary bladder cancer	7.04e-05	0.000949	CcSEcCtD
Ezetimibe—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.02e-05	0.000947	CcSEcCtD
Ezetimibe—Back pain—Methotrexate—urinary bladder cancer	7.01e-05	0.000945	CcSEcCtD
Ezetimibe—Pruritus—Etoposide—urinary bladder cancer	6.99e-05	0.000942	CcSEcCtD
Ezetimibe—Alopecia—Epirubicin—urinary bladder cancer	6.89e-05	0.000928	CcSEcCtD
Ezetimibe—Nausea—Gemcitabine—urinary bladder cancer	6.87e-05	0.000926	CcSEcCtD
Ezetimibe—Vomiting—Cisplatin—urinary bladder cancer	6.85e-05	0.000924	CcSEcCtD
Ezetimibe—Mental disorder—Epirubicin—urinary bladder cancer	6.83e-05	0.00092	CcSEcCtD
Ezetimibe—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.82e-05	0.000919	CcSEcCtD
Ezetimibe—Rash—Cisplatin—urinary bladder cancer	6.8e-05	0.000916	CcSEcCtD
Ezetimibe—Dermatitis—Cisplatin—urinary bladder cancer	6.79e-05	0.000916	CcSEcCtD
Ezetimibe—Malnutrition—Epirubicin—urinary bladder cancer	6.78e-05	0.000915	CcSEcCtD
Ezetimibe—Erythema—Epirubicin—urinary bladder cancer	6.78e-05	0.000915	CcSEcCtD
Ezetimibe—Diarrhoea—Etoposide—urinary bladder cancer	6.76e-05	0.000911	CcSEcCtD
Ezetimibe—Nausea—Fluorouracil—urinary bladder cancer	6.75e-05	0.000911	CcSEcCtD
Ezetimibe—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.73e-05	0.000907	CcSEcCtD
Ezetimibe—Anaemia—Methotrexate—urinary bladder cancer	6.7e-05	0.000903	CcSEcCtD
Ezetimibe—Flushing—Doxorubicin—urinary bladder cancer	6.69e-05	0.000902	CcSEcCtD
Ezetimibe—Flatulence—Epirubicin—urinary bladder cancer	6.68e-05	0.000901	CcSEcCtD
Ezetimibe—Back pain—Epirubicin—urinary bladder cancer	6.56e-05	0.000885	CcSEcCtD
Ezetimibe—Angiopathy—Doxorubicin—urinary bladder cancer	6.54e-05	0.000882	CcSEcCtD
Ezetimibe—Malaise—Methotrexate—urinary bladder cancer	6.54e-05	0.000881	CcSEcCtD
Ezetimibe—Dizziness—Etoposide—urinary bladder cancer	6.53e-05	0.000881	CcSEcCtD
Ezetimibe—Muscle spasms—Epirubicin—urinary bladder cancer	6.52e-05	0.000879	CcSEcCtD
Ezetimibe—Immune system disorder—Doxorubicin—urinary bladder cancer	6.51e-05	0.000878	CcSEcCtD
Ezetimibe—Mediastinal disorder—Doxorubicin—urinary bladder cancer	6.5e-05	0.000876	CcSEcCtD
Ezetimibe—Nausea—Cisplatin—urinary bladder cancer	6.4e-05	0.000863	CcSEcCtD
Ezetimibe—Alopecia—Doxorubicin—urinary bladder cancer	6.37e-05	0.000859	CcSEcCtD
Ezetimibe—Cough—Methotrexate—urinary bladder cancer	6.33e-05	0.000853	CcSEcCtD
Ezetimibe—Mental disorder—Doxorubicin—urinary bladder cancer	6.32e-05	0.000852	CcSEcCtD
Ezetimibe—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.29e-05	0.000849	CcSEcCtD
Ezetimibe—Vomiting—Etoposide—urinary bladder cancer	6.28e-05	0.000847	CcSEcCtD
Ezetimibe—Erythema—Doxorubicin—urinary bladder cancer	6.28e-05	0.000846	CcSEcCtD
Ezetimibe—Malnutrition—Doxorubicin—urinary bladder cancer	6.28e-05	0.000846	CcSEcCtD
Ezetimibe—Anaemia—Epirubicin—urinary bladder cancer	6.27e-05	0.000845	CcSEcCtD
Ezetimibe—Rash—Etoposide—urinary bladder cancer	6.23e-05	0.00084	CcSEcCtD
Ezetimibe—Dermatitis—Etoposide—urinary bladder cancer	6.22e-05	0.000839	CcSEcCtD
Ezetimibe—Headache—Etoposide—urinary bladder cancer	6.19e-05	0.000834	CcSEcCtD
Ezetimibe—Flatulence—Doxorubicin—urinary bladder cancer	6.18e-05	0.000834	CcSEcCtD
Ezetimibe—Arthralgia—Methotrexate—urinary bladder cancer	6.17e-05	0.000832	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—urinary bladder cancer	6.17e-05	0.000832	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—urinary bladder cancer	6.17e-05	0.000832	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.13e-05	0.000826	CcSEcCtD
Ezetimibe—Malaise—Epirubicin—urinary bladder cancer	6.12e-05	0.000825	CcSEcCtD
Ezetimibe—Discomfort—Methotrexate—urinary bladder cancer	6.1e-05	0.000822	CcSEcCtD
Ezetimibe—Back pain—Doxorubicin—urinary bladder cancer	6.07e-05	0.000819	CcSEcCtD
Ezetimibe—Muscle spasms—Doxorubicin—urinary bladder cancer	6.03e-05	0.000814	CcSEcCtD
Ezetimibe—Palpitations—Epirubicin—urinary bladder cancer	5.99e-05	0.000808	CcSEcCtD
Ezetimibe—Confusional state—Methotrexate—urinary bladder cancer	5.96e-05	0.000804	CcSEcCtD
Ezetimibe—Cough—Epirubicin—urinary bladder cancer	5.92e-05	0.000798	CcSEcCtD
Ezetimibe—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.92e-05	0.000798	CcSEcCtD
Ezetimibe—Infection—Methotrexate—urinary bladder cancer	5.88e-05	0.000792	CcSEcCtD
Ezetimibe—Nausea—Etoposide—urinary bladder cancer	5.87e-05	0.000791	CcSEcCtD
Ezetimibe—Hypertension—Epirubicin—urinary bladder cancer	5.86e-05	0.00079	CcSEcCtD
Ezetimibe—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.82e-05	0.000785	CcSEcCtD
Ezetimibe—Nervous system disorder—Methotrexate—urinary bladder cancer	5.8e-05	0.000782	CcSEcCtD
Ezetimibe—Anaemia—Doxorubicin—urinary bladder cancer	5.8e-05	0.000782	CcSEcCtD
Ezetimibe—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.79e-05	0.000781	CcSEcCtD
Ezetimibe—Myalgia—Epirubicin—urinary bladder cancer	5.78e-05	0.000779	CcSEcCtD
Ezetimibe—Chest pain—Epirubicin—urinary bladder cancer	5.78e-05	0.000779	CcSEcCtD
Ezetimibe—Arthralgia—Epirubicin—urinary bladder cancer	5.78e-05	0.000779	CcSEcCtD
Ezetimibe—Skin disorder—Methotrexate—urinary bladder cancer	5.75e-05	0.000775	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.74e-05	0.000773	CcSEcCtD
Ezetimibe—Discomfort—Epirubicin—urinary bladder cancer	5.71e-05	0.000769	CcSEcCtD
Ezetimibe—Malaise—Doxorubicin—urinary bladder cancer	5.66e-05	0.000763	CcSEcCtD
Ezetimibe—Dry mouth—Epirubicin—urinary bladder cancer	5.65e-05	0.000761	CcSEcCtD
Ezetimibe—Confusional state—Epirubicin—urinary bladder cancer	5.58e-05	0.000753	CcSEcCtD
Ezetimibe—Palpitations—Doxorubicin—urinary bladder cancer	5.55e-05	0.000748	CcSEcCtD
Ezetimibe—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.54e-05	0.000746	CcSEcCtD
Ezetimibe—Infection—Epirubicin—urinary bladder cancer	5.5e-05	0.000742	CcSEcCtD
Ezetimibe—Cough—Doxorubicin—urinary bladder cancer	5.48e-05	0.000738	CcSEcCtD
Ezetimibe—Nervous system disorder—Epirubicin—urinary bladder cancer	5.43e-05	0.000732	CcSEcCtD
Ezetimibe—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.42e-05	0.000731	CcSEcCtD
Ezetimibe—Hypertension—Doxorubicin—urinary bladder cancer	5.42e-05	0.000731	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.39e-05	0.000727	CcSEcCtD
Ezetimibe—Skin disorder—Epirubicin—urinary bladder cancer	5.38e-05	0.000725	CcSEcCtD
Ezetimibe—Insomnia—Methotrexate—urinary bladder cancer	5.35e-05	0.000721	CcSEcCtD
Ezetimibe—Myalgia—Doxorubicin—urinary bladder cancer	5.34e-05	0.00072	CcSEcCtD
Ezetimibe—Arthralgia—Doxorubicin—urinary bladder cancer	5.34e-05	0.00072	CcSEcCtD
Ezetimibe—Chest pain—Doxorubicin—urinary bladder cancer	5.34e-05	0.00072	CcSEcCtD
Ezetimibe—Paraesthesia—Methotrexate—urinary bladder cancer	5.31e-05	0.000716	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.31e-05	0.000715	CcSEcCtD
Ezetimibe—Discomfort—Doxorubicin—urinary bladder cancer	5.28e-05	0.000712	CcSEcCtD
Ezetimibe—Dyspnoea—Methotrexate—urinary bladder cancer	5.27e-05	0.000711	CcSEcCtD
Ezetimibe—Dry mouth—Doxorubicin—urinary bladder cancer	5.23e-05	0.000705	CcSEcCtD
Ezetimibe—Dyspepsia—Methotrexate—urinary bladder cancer	5.21e-05	0.000702	CcSEcCtD
Ezetimibe—Confusional state—Doxorubicin—urinary bladder cancer	5.17e-05	0.000696	CcSEcCtD
Ezetimibe—Decreased appetite—Methotrexate—urinary bladder cancer	5.14e-05	0.000693	CcSEcCtD
Ezetimibe—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.12e-05	0.000691	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.11e-05	0.000689	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—urinary bladder cancer	5.1e-05	0.000688	CcSEcCtD
Ezetimibe—Infection—Doxorubicin—urinary bladder cancer	5.09e-05	0.000686	CcSEcCtD
Ezetimibe—Pain—Methotrexate—urinary bladder cancer	5.06e-05	0.000682	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.04e-05	0.00068	CcSEcCtD
Ezetimibe—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.02e-05	0.000677	CcSEcCtD
Ezetimibe—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.02e-05	0.000676	CcSEcCtD
Ezetimibe—Insomnia—Epirubicin—urinary bladder cancer	5.01e-05	0.000675	CcSEcCtD
Ezetimibe—Skin disorder—Doxorubicin—urinary bladder cancer	4.98e-05	0.000671	CcSEcCtD
Ezetimibe—Paraesthesia—Epirubicin—urinary bladder cancer	4.97e-05	0.00067	CcSEcCtD
Ezetimibe—Dyspnoea—Epirubicin—urinary bladder cancer	4.94e-05	0.000665	CcSEcCtD
Ezetimibe—Feeling abnormal—Methotrexate—urinary bladder cancer	4.87e-05	0.000657	CcSEcCtD
Ezetimibe—Dyspepsia—Epirubicin—urinary bladder cancer	4.87e-05	0.000657	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.84e-05	0.000652	CcSEcCtD
Ezetimibe—Decreased appetite—Epirubicin—urinary bladder cancer	4.81e-05	0.000649	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.78e-05	0.000644	CcSEcCtD
Ezetimibe—Fatigue—Epirubicin—urinary bladder cancer	4.77e-05	0.000644	CcSEcCtD
Ezetimibe—Pain—Epirubicin—urinary bladder cancer	4.73e-05	0.000638	CcSEcCtD
Ezetimibe—Constipation—Epirubicin—urinary bladder cancer	4.73e-05	0.000638	CcSEcCtD
Ezetimibe—Urticaria—Methotrexate—urinary bladder cancer	4.7e-05	0.000634	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—urinary bladder cancer	4.68e-05	0.00063	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—urinary bladder cancer	4.68e-05	0.00063	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.67e-05	0.000629	CcSEcCtD
Ezetimibe—Insomnia—Doxorubicin—urinary bladder cancer	4.63e-05	0.000625	CcSEcCtD
Ezetimibe—Paraesthesia—Doxorubicin—urinary bladder cancer	4.6e-05	0.00062	CcSEcCtD
Ezetimibe—Dyspnoea—Doxorubicin—urinary bladder cancer	4.57e-05	0.000616	CcSEcCtD
Ezetimibe—Feeling abnormal—Epirubicin—urinary bladder cancer	4.56e-05	0.000615	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.53e-05	0.00061	CcSEcCtD
Ezetimibe—Dyspepsia—Doxorubicin—urinary bladder cancer	4.51e-05	0.000608	CcSEcCtD
Ezetimibe—Decreased appetite—Doxorubicin—urinary bladder cancer	4.45e-05	0.0006	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.42e-05	0.000596	CcSEcCtD
Ezetimibe—Fatigue—Doxorubicin—urinary bladder cancer	4.42e-05	0.000595	CcSEcCtD
Ezetimibe—Urticaria—Epirubicin—urinary bladder cancer	4.4e-05	0.000593	CcSEcCtD
Ezetimibe—Constipation—Doxorubicin—urinary bladder cancer	4.38e-05	0.000591	CcSEcCtD
Ezetimibe—Pain—Doxorubicin—urinary bladder cancer	4.38e-05	0.000591	CcSEcCtD
Ezetimibe—Abdominal pain—Epirubicin—urinary bladder cancer	4.38e-05	0.00059	CcSEcCtD
Ezetimibe—Body temperature increased—Epirubicin—urinary bladder cancer	4.38e-05	0.00059	CcSEcCtD
Ezetimibe—Hypersensitivity—Methotrexate—urinary bladder cancer	4.36e-05	0.000588	CcSEcCtD
Ezetimibe—Asthenia—Methotrexate—urinary bladder cancer	4.24e-05	0.000572	CcSEcCtD
Ezetimibe—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.22e-05	0.000569	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.19e-05	0.000565	CcSEcCtD
Ezetimibe—Pruritus—Methotrexate—urinary bladder cancer	4.19e-05	0.000564	CcSEcCtD
Ezetimibe—Hypersensitivity—Epirubicin—urinary bladder cancer	4.08e-05	0.00055	CcSEcCtD
Ezetimibe—Urticaria—Doxorubicin—urinary bladder cancer	4.07e-05	0.000549	CcSEcCtD
Ezetimibe—Abdominal pain—Doxorubicin—urinary bladder cancer	4.05e-05	0.000546	CcSEcCtD
Ezetimibe—Body temperature increased—Doxorubicin—urinary bladder cancer	4.05e-05	0.000546	CcSEcCtD
Ezetimibe—Diarrhoea—Methotrexate—urinary bladder cancer	4.05e-05	0.000546	CcSEcCtD
Ezetimibe—Asthenia—Epirubicin—urinary bladder cancer	3.97e-05	0.000536	CcSEcCtD
Ezetimibe—Pruritus—Epirubicin—urinary bladder cancer	3.92e-05	0.000528	CcSEcCtD
Ezetimibe—Dizziness—Methotrexate—urinary bladder cancer	3.91e-05	0.000527	CcSEcCtD
Ezetimibe—Diarrhoea—Epirubicin—urinary bladder cancer	3.79e-05	0.000511	CcSEcCtD
Ezetimibe—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.77e-05	0.000509	CcSEcCtD
Ezetimibe—Vomiting—Methotrexate—urinary bladder cancer	3.76e-05	0.000507	CcSEcCtD
Ezetimibe—Rash—Methotrexate—urinary bladder cancer	3.73e-05	0.000503	CcSEcCtD
Ezetimibe—Dermatitis—Methotrexate—urinary bladder cancer	3.73e-05	0.000502	CcSEcCtD
Ezetimibe—Headache—Methotrexate—urinary bladder cancer	3.71e-05	0.0005	CcSEcCtD
Ezetimibe—Asthenia—Doxorubicin—urinary bladder cancer	3.68e-05	0.000496	CcSEcCtD
Ezetimibe—Dizziness—Epirubicin—urinary bladder cancer	3.66e-05	0.000494	CcSEcCtD
Ezetimibe—Pruritus—Doxorubicin—urinary bladder cancer	3.62e-05	0.000489	CcSEcCtD
Ezetimibe—Vomiting—Epirubicin—urinary bladder cancer	3.52e-05	0.000475	CcSEcCtD
Ezetimibe—Nausea—Methotrexate—urinary bladder cancer	3.51e-05	0.000474	CcSEcCtD
Ezetimibe—Diarrhoea—Doxorubicin—urinary bladder cancer	3.5e-05	0.000473	CcSEcCtD
Ezetimibe—Rash—Epirubicin—urinary bladder cancer	3.49e-05	0.000471	CcSEcCtD
Ezetimibe—Dermatitis—Epirubicin—urinary bladder cancer	3.49e-05	0.00047	CcSEcCtD
Ezetimibe—Headache—Epirubicin—urinary bladder cancer	3.47e-05	0.000468	CcSEcCtD
Ezetimibe—Dizziness—Doxorubicin—urinary bladder cancer	3.39e-05	0.000457	CcSEcCtD
Ezetimibe—Nausea—Epirubicin—urinary bladder cancer	3.29e-05	0.000443	CcSEcCtD
Ezetimibe—Vomiting—Doxorubicin—urinary bladder cancer	3.26e-05	0.000439	CcSEcCtD
Ezetimibe—Rash—Doxorubicin—urinary bladder cancer	3.23e-05	0.000435	CcSEcCtD
Ezetimibe—Dermatitis—Doxorubicin—urinary bladder cancer	3.23e-05	0.000435	CcSEcCtD
Ezetimibe—Headache—Doxorubicin—urinary bladder cancer	3.21e-05	0.000433	CcSEcCtD
Ezetimibe—Nausea—Doxorubicin—urinary bladder cancer	3.04e-05	0.00041	CcSEcCtD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.29e-05	0.000289	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP4B1—urinary bladder cancer	2.27e-05	0.000287	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	2.24e-05	0.000282	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—EP300—urinary bladder cancer	2.22e-05	0.00028	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—GSTP1—urinary bladder cancer	2.2e-05	0.000277	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—NAT2—urinary bladder cancer	2.19e-05	0.000276	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.15e-05	0.000271	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—SLC19A1—urinary bladder cancer	2.15e-05	0.000271	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	2.14e-05	0.00027	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PRSS3—urinary bladder cancer	2.09e-05	0.000264	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP4B1—urinary bladder cancer	2.08e-05	0.000263	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.07e-05	0.00026	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—TYMP—urinary bladder cancer	2.06e-05	0.00026	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—TYMP—urinary bladder cancer	2.06e-05	0.00026	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—TYMS—urinary bladder cancer	2.04e-05	0.000257	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	2.04e-05	0.000257	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	2.02e-05	0.000255	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTGS2—urinary bladder cancer	2.02e-05	0.000255	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—NCOR1—urinary bladder cancer	2.02e-05	0.000255	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—GSTM1—urinary bladder cancer	2.02e-05	0.000255	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	2e-05	0.000252	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.99e-05	0.000251	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.98e-05	0.000249	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—SLC19A1—urinary bladder cancer	1.97e-05	0.000248	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.96e-05	0.000246	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	1.95e-05	0.000246	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTGS2—urinary bladder cancer	1.95e-05	0.000245	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	1.94e-05	0.000244	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—GPX1—urinary bladder cancer	1.93e-05	0.000244	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	1.93e-05	0.000243	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	1.92e-05	0.000242	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	1.9e-05	0.000239	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—ERCC2—urinary bladder cancer	1.9e-05	0.000239	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—RRM2—urinary bladder cancer	1.89e-05	0.000238	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	1.86e-05	0.000235	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—NAT2—urinary bladder cancer	1.86e-05	0.000235	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NAT2—urinary bladder cancer	1.86e-05	0.000235	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	1.82e-05	0.00023	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—MTHFR—urinary bladder cancer	1.78e-05	0.000225	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PRSS3—urinary bladder cancer	1.78e-05	0.000224	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTEN—urinary bladder cancer	1.76e-05	0.000222	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ENO2—urinary bladder cancer	1.75e-05	0.000221	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—HPGDS—urinary bladder cancer	1.75e-05	0.000221	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GSTT1—urinary bladder cancer	1.7e-05	0.000214	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTEN—urinary bladder cancer	1.7e-05	0.000214	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—EP300—urinary bladder cancer	1.68e-05	0.000212	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—TYMP—urinary bladder cancer	1.67e-05	0.000211	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	1.65e-05	0.000208	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—EP300—urinary bladder cancer	1.62e-05	0.000204	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—RRM2—urinary bladder cancer	1.61e-05	0.000203	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—RRM2—urinary bladder cancer	1.61e-05	0.000203	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.59e-05	0.000201	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.54e-05	0.000194	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	1.53e-05	0.000193	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—NAT2—urinary bladder cancer	1.51e-05	0.000191	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ENO2—urinary bladder cancer	1.49e-05	0.000188	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—HPGDS—urinary bladder cancer	1.49e-05	0.000188	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ENO2—urinary bladder cancer	1.49e-05	0.000188	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—HPGDS—urinary bladder cancer	1.49e-05	0.000188	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.48e-05	0.000187	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.47e-05	0.000186	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	1.46e-05	0.000184	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	1.45e-05	0.000183	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	1.45e-05	0.000183	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PPARG—urinary bladder cancer	1.45e-05	0.000182	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	0.000182	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	0.000182	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	1.42e-05	0.000179	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.42e-05	0.000179	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—TYMP—urinary bladder cancer	1.42e-05	0.000179	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—NQO1—urinary bladder cancer	1.41e-05	0.000178	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CREBBP—urinary bladder cancer	1.39e-05	0.000175	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	1.39e-05	0.000175	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.35e-05	0.00017	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.34e-05	0.000169	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	1.34e-05	0.000168	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.33e-05	0.000167	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—RRM2—urinary bladder cancer	1.31e-05	0.000165	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NAT2—urinary bladder cancer	1.28e-05	0.000162	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.27e-05	0.00016	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTO2—urinary bladder cancer	1.27e-05	0.00016	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NAT1—urinary bladder cancer	1.27e-05	0.00016	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.25e-05	0.000158	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.24e-05	0.000156	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.22e-05	0.000154	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—HPGDS—urinary bladder cancer	1.21e-05	0.000152	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ENO2—urinary bladder cancer	1.21e-05	0.000152	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—NQO1—urinary bladder cancer	1.2e-05	0.000151	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NQO1—urinary bladder cancer	1.2e-05	0.000151	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	1.2e-05	0.000151	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GSTP1—urinary bladder cancer	1.18e-05	0.000148	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GSTT1—urinary bladder cancer	1.17e-05	0.000148	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.16e-05	0.000147	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.16e-05	0.000146	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTGS2—urinary bladder cancer	1.14e-05	0.000143	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	1.11e-05	0.00014	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	1.11e-05	0.00014	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—RRM2—urinary bladder cancer	1.11e-05	0.00014	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.1e-05	0.000139	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—TYMS—urinary bladder cancer	1.09e-05	0.000138	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—NCOR1—urinary bladder cancer	1.08e-05	0.000136	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GSTM1—urinary bladder cancer	1.08e-05	0.000136	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.08e-05	0.000136	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	1.08e-05	0.000136	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.07e-05	0.000135	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.06e-05	0.000134	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.06e-05	0.000133	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.04e-05	0.000131	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.04e-05	0.000131	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GPX1—urinary bladder cancer	1.04e-05	0.000131	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ENO2—urinary bladder cancer	1.03e-05	0.000129	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—HPGDS—urinary bladder cancer	1.03e-05	0.000129	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	0.000128	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.02e-05	0.000128	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.01e-05	0.000127	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GSTP1—urinary bladder cancer	1e-05	0.000126	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GSTP1—urinary bladder cancer	1e-05	0.000126	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTT1—urinary bladder cancer	9.95e-06	0.000125	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTEN—urinary bladder cancer	9.93e-06	0.000125	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	9.85e-06	0.000124	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—NQO1—urinary bladder cancer	9.75e-06	0.000123	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.68e-06	0.000122	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PRSS3—urinary bladder cancer	9.6e-06	0.000121	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—MTHFR—urinary bladder cancer	9.56e-06	0.00012	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—EP300—urinary bladder cancer	9.47e-06	0.000119	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	9.39e-06	0.000118	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.32e-06	0.000117	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—TYMS—urinary bladder cancer	9.3e-06	0.000117	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—TYMS—urinary bladder cancer	9.3e-06	0.000117	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GSTM1—urinary bladder cancer	9.2e-06	0.000116	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—NCOR1—urinary bladder cancer	9.2e-06	0.000116	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	9.2e-06	0.000116	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	9.2e-06	0.000116	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	9.08e-06	0.000115	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	9.06e-06	0.000114	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	8.93e-06	0.000113	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GPX1—urinary bladder cancer	8.81e-06	0.000111	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GPX1—urinary bladder cancer	8.81e-06	0.000111	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.67e-06	0.000109	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ERCC2—urinary bladder cancer	8.65e-06	0.000109	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	8.65e-06	0.000109	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	8.64e-06	0.000109	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	8.41e-06	0.000106	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NQO1—urinary bladder cancer	8.27e-06	0.000104	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	8.23e-06	0.000104	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	8.13e-06	0.000103	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	8.13e-06	0.000102	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—MTHFR—urinary bladder cancer	8.13e-06	0.000102	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.8e-06	9.84e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.8e-06	9.84e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPARG—urinary bladder cancer	7.75e-06	9.77e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—TYMP—urinary bladder cancer	7.68e-06	9.67e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—TYMS—urinary bladder cancer	7.56e-06	9.53e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.56e-06	9.53e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	7.53e-06	9.49e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	7.47e-06	9.42e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	7.47e-06	9.42e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	7.45e-06	9.39e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	7.45e-06	9.39e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.37e-06	9.29e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.21e-06	9.09e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GPX1—urinary bladder cancer	7.16e-06	9.02e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.14e-06	9e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	7.03e-06	8.86e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.02e-06	8.84e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.96e-06	8.77e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NAT2—urinary bladder cancer	6.94e-06	8.75e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	6.93e-06	8.73e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTP1—urinary bladder cancer	6.9e-06	8.7e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	6.85e-06	8.63e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	6.85e-06	8.63e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	6.6e-06	8.33e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPARG—urinary bladder cancer	6.59e-06	8.31e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPARG—urinary bladder cancer	6.59e-06	8.31e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	6.56e-06	8.27e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	6.44e-06	8.12e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.43e-06	8.1e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—TYMS—urinary bladder cancer	6.41e-06	8.09e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NCOR1—urinary bladder cancer	6.34e-06	7.99e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTM1—urinary bladder cancer	6.34e-06	7.99e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CREBBP—urinary bladder cancer	6.33e-06	7.98e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	6.33e-06	7.98e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.19e-06	7.8e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	6.1e-06	7.69e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GPX1—urinary bladder cancer	6.07e-06	7.65e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.07e-06	7.65e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	6.05e-06	7.63e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—RRM2—urinary bladder cancer	5.99e-06	7.55e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ERCC2—urinary bladder cancer	5.96e-06	7.51e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.92e-06	7.46e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—MTHFR—urinary bladder cancer	5.6e-06	7.06e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—HPGDS—urinary bladder cancer	5.55e-06	6.99e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ENO2—urinary bladder cancer	5.55e-06	6.99e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.38e-06	6.78e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPARG—urinary bladder cancer	5.36e-06	6.75e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTEN—urinary bladder cancer	5.32e-06	6.7e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTGS2—urinary bladder cancer	5.18e-06	6.54e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	5.18e-06	6.54e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	5.14e-06	6.49e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—EP300—urinary bladder cancer	5.07e-06	6.39e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.04e-06	6.35e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	4.91e-06	6.19e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.73e-06	5.96e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	4.71e-06	5.94e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPARG—urinary bladder cancer	4.54e-06	5.73e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTEN—urinary bladder cancer	4.52e-06	5.7e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTEN—urinary bladder cancer	4.52e-06	5.7e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.47e-06	5.64e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CREBBP—urinary bladder cancer	4.37e-06	5.5e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—EP300—urinary bladder cancer	4.31e-06	5.44e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—EP300—urinary bladder cancer	4.31e-06	5.44e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.28e-06	5.39e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	4.21e-06	5.31e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	3.86e-06	4.87e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.73e-06	4.7e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.69e-06	4.65e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTEN—urinary bladder cancer	3.67e-06	4.63e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTGS2—urinary bladder cancer	3.57e-06	4.51e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—EP300—urinary bladder cancer	3.5e-06	4.42e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.47e-06	4.37e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.43e-06	4.32e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.43e-06	4.32e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.42e-06	4.31e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.42e-06	4.31e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	3.37e-06	4.24e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.32e-06	4.18e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.28e-06	4.14e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.22e-06	4.06e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—EP300—urinary bladder cancer	3.21e-06	4.05e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTEN—urinary bladder cancer	3.12e-06	3.93e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.03e-06	3.82e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—EP300—urinary bladder cancer	2.97e-06	3.75e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.76e-06	3.47e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.46e-06	3.1e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.36e-06	2.97e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.3e-06	2.9e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.14e-06	2.69e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.11e-06	2.66e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.11e-06	2.66e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.02e-06	2.55e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.99e-06	2.5e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.93e-06	2.44e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.87e-06	2.35e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.69e-06	2.12e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—EP300—urinary bladder cancer	1.61e-06	2.03e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.51e-06	1.91e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.45e-06	1.83e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.19e-06	1.5e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.04e-06	1.31e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.9e-07	1.25e-05	CbGpPWpGaD
